Lilly and Hims & Hers sign a self-pay deal for Zepbound and Foundayo. What the announcement actually commits to
Two days, two telehealth companies, one drugmaker. On November 5 it was LifeMD saying its own pharmacy could fill Lilly's cash-pay GLP-1s. On the morning of November 6, Eli Lilly and Hims & Hers announced their own agreement for the same two medicines. Hims & Hers is the company FDA named in a February 2026 statement about compounded GLP-1 marketing, so this one drew a lot of double-takes. Here's what the two companies put in writing, and what they left out.
Facts are as of November 7, 2026. Sources, with retrieval dates, are at the bottom.
The announcement in four lines
- Lilly and Hims & Hers announced an agreement covering Zepbound (tirzepatide) and Foundayo (orforglipron), both FDA-approved Lilly medicines. [V]
- People whose prescription comes from a licensed clinician working through Hims & Hers can pay Lilly's standard self-pay prices, the ones open to any patient, and stay on the platform the whole way. [V]
- Per the release, Hims & Hers has never sold compounded versions of Lilly's GLP-1s and pledges it won't start. [V]
- Both companies say they'll protect independent clinical decision-making by the platform's providers. [V]
What was announced on November 6
The joint release went out at 6:47 a.m. Eastern on November 6, 2026, through PR Newswire under Lilly's name, and Hims & Hers posted the same text in its newsroom that day. [V] It describes one path from start to finish: a visit with a licensed clinician through the platform, a prescription only if that clinician decides it fits, and an FDA-approved Lilly medicine shipped to the patient's home. [V]
The release gives starting self-pay prices of $149 a month for Foundayo and $299 a month for Zepbound, and frames them as the same prices available to any self-pay patient. [V] We're reporting those figures because they're part of the news, not because we're comparing anyone's prices. Insurance isn't part of what's described. [V]
Lilly's Ilya Yuffa, who leads Lilly USA, said the company wants to reach patients "where they already are." [V] Andrew Dudum, who co-founded Hims & Hers and runs it as CEO, called Lilly one of the most innovative drug companies in history. [V] Both quotes are about access and partnership. Neither is a claim about what the medicines do for any one person.
“Hims & Hers has never offered access to compounded copies of Lilly's GLP-1s, and has committed not to do so in the future.”
The no-compounding line, read closely
That sentence is the part people will quote, so it's worth reading word by word. It covers compounded copies of Lilly's GLP-1s: tirzepatide and orforglipron. [V] It says nothing either way about other compounded products on the platform. [V] The release doesn't mention semaglutide, which is Novo Nordisk's molecule, and it doesn't mention the peptide plans Hims & Hers announced on October 29 (sermorelin, glutathione, NAD+ and others, with BPC-157 and TB-500 "when allowable"). [V] Our Peptides+ and HHS six-peptide brief covers that earlier announcement.
It's also a company commitment inside a commercial deal, not an FDA order or a court ruling. [V] Hims & Hers' own forward-looking statement lists its ability to keep up the agreement, "including with respect to pricing, fulfillment, and Hims & Hers' commitments," among its business risks. [V]
Why this pairing caught people's attention
The regulatory history is public. In a September 9, 2025 warning letter, FDA objected to Hims & Hers website claims about compounded semaglutide, including "Same active ingredient as Ozempic and Wegovy." [V] FDA's February 6, 2026 statement on non-approved GLP-1s named Hims & Hers when it said the agency planned to restrict GLP-1 ingredients headed into non-approved compounded drugs that companies mass-market as alternatives to approved ones. [V] Our Hims & Hers, FTC and FDA explainer lays out who said what, and keeps the FTC's separate, still-pending lawsuit apart from FDA's compounding statements.
Against that backdrop, a drugmaker signing a branded supply-and-pricing deal with the same platform is a shift in tone. [U] That's our reading of the timeline, not something either company said.
Hims & Hers vs LifeMD: two routes to the same two medicines
Both announcements involve the same Lilly products at Lilly's self-pay pricing. [V] The difference is who fills the prescription.
LifeMD (November 5). LifeMD said its own affiliated, licensed mail-order pharmacy would dispense and ship the medicines nationwide. [V] Our LifeMD brief has the details.
Hims & Hers (November 6). The release says the medicine is shipped to the patient's home and that patients don't leave the Hims & Hers platform. It doesn't say which pharmacy dispenses it. [V] We didn't find that detail in either version of the release, so we aren't guessing. [U]
Neither route is compounding. Both describe the FDA-approved finished products. [V] If the three lanes (approved, compounded, "research-labeled") still blur together, our GLP-1 explainer sorts them, and the Foundayo approval page covers how the oral pill got through FDA.
Three quick misreadings
"Hims & Hers stopped all compounding." The commitment in the release is about compounded copies of Lilly's GLP-1s. [V]
"FDA approved this partnership." It's a commercial agreement between two companies. No FDA action is described. [V]
"Self-pay means insurance pays some of it." Self-pay means the patient pays the cash price. The release doesn't describe insurance billing. [V]
What the release leaves open
There's no separate start date beyond "today announced an agreement," and Hims & Hers lists "timing and logistical considerations" of the rollout among its risks. [V] There's no list of which states or patients qualify, beyond "eligible patients" with a prescription. [V] And "pricing starts at" means the release gives a floor, not every price point. [V] We didn't open Lilly's own pricing pages for this brief. [U]
Peptide Policy Watch
Lilly and Hims & Hers sign a self-pay deal for Zepbound and Foundayo. What the announcement actually commits to
Printable checklist
A short list for your clinician or pharmacist
Print or copy these questions for your next visit with a clinician or pharmacist.
- Is the medicine I'd get the FDA-approved product, or a compounded preparation?
- Which pharmacy actually fills and ships it?
- Is this a cash price, and does any of it go through my insurance?
- If I'm switching from a compounded version, what changes between the two?
Print view Select it, then use your browser’s Print command to print only this box.
Where this leaves the telehealth GLP-1 picture
A week ago, the loudest telehealth GLP-1 news was about warning letters and ad challenges. Our NAD / Good Life brief covers a November 4 decision on compounded tirzepatide claims. This week, two telehealth companies announced branded self-pay channels with Lilly on back-to-back days. [V] Whether that becomes the normal path, or stays a pair of headlines, depends on rollout details neither release spells out yet. If Lilly or Hims & Hers posts more specifics, such as a pharmacy partner, a launch date or more medicines, we'll update this page.
Sources (retrieved November 7, 2026)
- Eli Lilly and Company and Hims & Hers Health, Inc., "Lilly and Hims & Hers expand access to FDA-approved Lilly medicines," PR Newswire, November 6, 2026, 06:47 ET [V] — https://www.prnewswire.com/news-releases/lilly-and-hims--hers-expand-access-to-fda-approved-lilly-medicines-302931979.html
- Hims & Hers newsroom, "Lilly and Hims & Hers Expand Access to FDA-Approved Lilly Medicines," November 6, 2026 (same text, company posting) [V] — https://news.hims.com/newsroom/lilly-and-hims-hers-expand-access-to-fda-approved-lilly-medicines
- FDA warning letter to Hims & Hers Health, Inc., September 9, 2025 (MARCS-CMS 716567) [V] — https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hims-hers-health-inc-dba-hims-716567-09092025
- FDA, "FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs," February 6, 2026 [V] — https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs
- Hims & Hers newsroom, Andrew Dudum, "Expanding Safe Access to Peptides," October 29, 2026 (company statement) [V] — https://news.hims.com/newsroom/expanding-safe-access-to-peptides
- LifeMD, Inc., release via GlobeNewswire, November 5, 2026 [V] — https://www.globenewswire.com/news-release/2026/11/05/3396309/0/en/lifemd-expands-access-to-lilly-s-self-pay-glp-1-medicines-enabling-option-to-dispense-and-ship-directly-to-patients-nationwide.html
Cite or link to this page
Peptide Policy Watch staff. “Lilly and Hims & Hers sign a self-pay deal for Zepbound and Foundayo. What the announcement actually commits to.” Peptide Policy Watch. Published November 7, 2026. https://peptidepolicywatch.com/2026/11/07/lilly-hims-hers-self-pay-zepbound-foundayo-agreement/
Link: https://peptidepolicywatch.com/2026/11/07/lilly-hims-hers-self-pay-zepbound-foundayo-agreement/
Spot a mistake? See how we source and our corrections policy.
Image: AI-generated. Image credits